Literature DB >> 28139239

Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy.

Mohamed A Bedaiwy1, Catherine Allaire2, Sukinah Alfaraj2.   

Abstract

Endometriosis can recur after either surgical or medical therapy. Long-term medical therapy is implemented to treat symptoms or prevent recurrence. Dienogest and gonadotropin-releasing hormone (GnRH) analogues with hormone add-back therapy seem to be equally effective for long-term treatment of pain symptoms associated with endometriosis. There is insufficient evidence to support the superiority of one therapy over the other. However, add-back hormone therapy (HT) is recommended for patients using GnRH agonists. The treatment selection depends on therapeutic effectiveness, tolerability, drug cost, the physician's experience, and expected patient compliance.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dienogest; GnRH-a; endometriosis; hormone add-back; long term

Mesh:

Substances:

Year:  2017        PMID: 28139239     DOI: 10.1016/j.fertnstert.2016.12.024

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  18 in total

Review 1.  Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.

Authors:  Alexandra Traila; Patriciu Achimas-Cadariu; Delia Dima; Romeo Micu
Journal:  Cancer Manag Res       Date:  2018-06-13       Impact factor: 3.989

Review 2.  Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment.

Authors:  Edgardo Rolla
Journal:  F1000Res       Date:  2019-04-23

3.  Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain.

Authors:  Salvatore Caruso; Marco Iraci; Stefano Cianci; Salvatore Giovanni Vitale; Valentina Fava; Antonio Cianci
Journal:  J Pain Res       Date:  2019-07-29       Impact factor: 3.133

4.  Significant risk factors for malignant transformation of ovarian endometrioma during dienogest treatment: a case report and retrospective study.

Authors:  Michiko Honda; Wataru Isono; Akira Tsuchiya; Ako Saito; Hiroko Tsuchiya; Reiko Matsuyama; Akihisa Fujimoto; Osamu Nishii
Journal:  J Med Case Rep       Date:  2019-10-22

5.  Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men.

Authors:  Richard A Anderson; Jennifer Cormier; Ruth Thieroff-Ekerdt; Malcolm Boyce; Frans van den Berg; Daniel Grau; David Turnquist; Deya Corzo; Philip Graham
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

6.  Pre- and postsurgical medical therapy for endometriosis surgery.

Authors:  Innie Chen; Veerle B Veth; Abdul J Choudhry; Ally Murji; Andrew Zakhari; Amanda Y Black; Carmina Agarpao; Jacques Wm Maas
Journal:  Cochrane Database Syst Rev       Date:  2020-11-18

7.  Daily Vaginal Application of Dienogest (Visanne©) for 3 Months in Symptomatic Deeply Infiltrating Rectovaginal Endometriosis: A Possible New Treatment Approach?

Authors:  Andreas D Ebert
Journal:  Case Rep Obstet Gynecol       Date:  2018-05-10

8.  Characteristics and long-term outcomes of perineal endometriosis: A retrospective study.

Authors:  Yu Liu; Ruyu Pi; Hong Luo; Wei Wang; Xia Zhao; Xiaorong Qi
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

9.  Effects of cisplatin on surgically induced endometriosis in a rat model.

Authors:  Zhanfei Li; Huibing Liu; Jinghe Lang; Guorui Zhang; Zhengxing He
Journal:  Oncol Lett       Date:  2018-08-07       Impact factor: 2.967

10.  Jiawei Foshou San Induces Apoptosis in Ectopic Endometrium Based on Systems Pharmacology, Molecular Docking, and Experimental Evidence.

Authors:  Jiahui Wei; Binxin Zhao; Chengling Zhang; Bingbing Shen; Ying Zhang; Changxi Li; Yi Chen
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.